{"id":"NCT01492686","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","officialTitle":"Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2014-09","completion":"2014-10","firstPosted":"2011-12-15","resultsPosted":"2018-12-31","lastUpdate":"2018-12-31"},"enrollment":137,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"interventions":[{"type":"DRUG","name":"MCI-186","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"MCI-186 in open label phase","otherNames":[]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"},{"label":"Arm 2","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186 to the ALS patients.","primaryOutcome":{"measure":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","timeFrame":"baseline and 24 weeks","effectByArm":[{"arm":"MCI-186","deltaMin":-5.01,"sd":0.64},{"arm":"Placebo of MCI-186","deltaMin":-7.5,"sd":0.66}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["28522181","28872920","37525592","28872913"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":69},"commonTop":["Contusion","Constipation","Dysphagia","Nasopharyngitis","Dermatitis contact"]}}